The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that presently available data does not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based diabetes therapies.

Great strides have been made recently in predicting who is most likely to develop type 1 diabetes, allowing researchers to identify the disease at the earliest stages of development and potentially intervene to preserve beta cell function at a much earlier stage and ultimately prevent onset of symptomatic diabetes.